Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L H Patterson

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
European Journal of Biochemistry|September 22, 1999
Cu/Zn superoxide dismutase in excretory-secretory products of the human hookworm Necator americanus. An electron paramagnetic spectrometry studyF A Taiwo, P M Brophy, D I Pritchard, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 25, 2004
A proteomic approach to the identification of cytochrome P450 isoforms in male and female rat liver by nanoscale liquid chromatography-electrospray ionization-tandem mass spectrometryS Nisar, C S Lane, A F Wilderspin, et al.
Biochemical Pharmacology|October 23, 1998
Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolitesS M Bailey, A D Lewis, R J Knox, et al.
Biochemical Pharmacology|July 13, 2001
Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging speciesS M Bailey, A D Lewis, L H Patterson, et al.
Advanced Drug Delivery Reviews|November 3, 2004
Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cellsR J Errington, S M Ameer-Beg, B Vojnovic, et al.
The British Journal of Cancer. Supplement|July 1, 1996
Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiationS R McKeown, O P Friery, I A McIntyre, et al.
British Journal of Cancer|February 1, 1996
DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cellsM V Hejmadi, S R McKeown, O P Friery, et al.
British Journal of Cancer|June 23, 2000
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agentL H Patterson, S R McKeown, K Ruparelia, et al.
British Journal of Cancer|August 17, 2001
The chemopotentiation of cisplatin by the novel bioreductive drug AQ4NR Gallagher, C M Hughes, M M Murray, et al.
The British Journal of Cancer. Supplement|July 1, 1996
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4NW R Wilson, W A Denny, S M Pullen, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
European Journal of Biochemistry|September 22, 1999
Cu/Zn superoxide dismutase in excretory-secretory products of the human hookworm Necator americanus. An electron paramagnetic spectrometry studyF A Taiwo, P M Brophy, D I Pritchard, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 25, 2004
A proteomic approach to the identification of cytochrome P450 isoforms in male and female rat liver by nanoscale liquid chromatography-electrospray ionization-tandem mass spectrometryS Nisar, C S Lane, A F Wilderspin, et al.
Biochemical Pharmacology|October 23, 1998
Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolitesS M Bailey, A D Lewis, R J Knox, et al.
Biochemical Pharmacology|July 13, 2001
Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging speciesS M Bailey, A D Lewis, L H Patterson, et al.
Advanced Drug Delivery Reviews|November 3, 2004
Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cellsR J Errington, S M Ameer-Beg, B Vojnovic, et al.
The British Journal of Cancer. Supplement|July 1, 1996
Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiationS R McKeown, O P Friery, I A McIntyre, et al.
British Journal of Cancer|February 1, 1996
DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cellsM V Hejmadi, S R McKeown, O P Friery, et al.
British Journal of Cancer|June 23, 2000
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agentL H Patterson, S R McKeown, K Ruparelia, et al.
British Journal of Cancer|August 17, 2001
The chemopotentiation of cisplatin by the novel bioreductive drug AQ4NR Gallagher, C M Hughes, M M Murray, et al.
The British Journal of Cancer. Supplement|July 1, 1996
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4NW R Wilson, W A Denny, S M Pullen, et al.
Pageof 7